Company Akeso, Inc. BOERSE MUENCHEN

Equities

4RY

KYG0146B1032

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per region

Ratings for Akeso, Inc.

EPS Revisions

Quarterly revenue - Rate of surprise

Sector Bio Therapeutic Drugs

Real-time BOERSE MUENCHEN Other stock markets 01:14:10 04/07/2024 am IST			5-day change	1st Jan Change
4.46 ^EUR	+0.45%		-2.20%	-16.23%

01/07	Akeso, Inc. Announces Change of Directors	CI
04/06	Akeso Expands Territory of License Agreement for Lung Cancer Drug	MT

Akeso Inc is an investment holding company mainly engaged in the research and development of biological products. The Company is dedicated to addressing global unmet medical needs in oncology, immunology and other therapeutic areas. The Company's main products include AK104, AK105, AK112 and AK109. The Company conducts its businesses within the China market and to overseas markets.

HKD in Million	2022	Weight	2023	Weight	Delta
Therapies 100.0 %	974	100.0 %	5,002	100.0 %	+413.45%

HKD in Million	2022	Weight	2023	Weight	Delta
United States 64.8 %	-	-	3,239	64.8 %	-
China 35.2 %	974	100.0 %	1,761	35.2 %	+80.77%
Other Regions 0.0 %	0	0.0 %	1	0.0 %	-

Managers	Title	Age	Since
Baiyong Li FOU	Founder	56	19/12/19
Peng Zhang FOU	Founder	48	19/12/19
Michelle Xia CEO	Chief Executive Officer	57	19/12/19
Zhongmin Wang FOU	Founder	55	19/12/19
Michael Chen PRN	Corporate Officer/Principal	-	30/20/30
Xin Feng Zhang PRN	Corporate Officer/Principal	-	17/20/17

Members of the board	Title	Age	Since
Bo Tan BRD	Director/Board Member	51	01/20/01
Zhongmin Wang FOU	Founder	55	19/12/19
Yan Xu BRD	Director/Board Member	61	01/20/01
Michelle Xia CEO	Chief Executive Officer	57	19/12/19
Baiyong Li FOU	Founder	56	19/12/19
Jun Wen Zeng BRD	Director/Board Member	63	-
Yu Xia BRD	Director/Board Member	54	01/19/01
Yi Zhou BRD	Director/Board Member	44	01/19/01
Rong Gang Xie BRD	Director/Board Member	39	19/20/19

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	865,857,176	634,964,039 ( 73.33 %)	0	73.33 %

Name	Equities	%	Valuation
Xia Yu Family 6.672 %	57,771,042	6.672 %	325 M €
Green Court Capital Management Ltd. 5.019 %	43,453,668	5.019 %	244 M €
Li Bai Yong Family 4.936 %	42,738,554	4.936 %	240 M €
Shenzhen Capital Group Co., Ltd. 4.857 %	42,052,529	4.857 %	237 M €
Xun Zheng 4.836 %	41,874,000	4.836 %	236 M €
Zhang Peng Family 4.034 %	34,929,065	4.034 %	196 M €
Zhongmin Wang 3.637 %	31,492,881	3.637 %	177 M €
Michelle Xia 2.425 %	21,000,000	2.425 %	118 M €
Luo Wenfeng 1.664 %	14,406,217	1.664 %	81 M €
Wang Zhong Min Family 1.583 %	13,706,442	1.583 %	77 M €

Akeso, Inc.

Torch Development Zone No.6 Shennong Road

528437, Zhongshan

http://www.akesobio.com/en/

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

35.18 CNY

Average target price

55.14 CNY

Spread / Average Target

+56.75%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+15.58%	122B
REGENERON PHARMACEUTICALS, INC.	+16.60%	113B
ARGENX SE	+17.55%	26.22B
BIONTECH SE	-24.33%	19.01B
GENMAB A/S	-19.14%	15.71B
BEIGENE, LTD.	-17.95%	15.22B
WUXI APPTEC CO., LTD.	-46.81%	14.72B
SAREPTA THERAPEUTICS, INC.	+58.78%	14.58B
NEUROCRINE BIOSCIENCES, INC.	+4.91%	13.84B

Bio Therapeutic Drugs